Navamedic ASA to Acquire dne pharma Business
June 23, 2025
Navamedic ASA has entered into an agreement to acquire the business of Norwegian addiction-treatment company dne pharma for total consideration of up to NOK 225 million. The acquisition includes dne pharma’s product portfolio, key employees, contracts, IP, licenses, and distribution agreements, and is expected to close in July 2025 subject to approval of Navamedic’s partially underwritten rights issue.
- Buyers
- Navamedic ASA
- Targets
- dne pharma
- Industry
- Pharmaceuticals
- Location
- Norway
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
NAMSA to Acquire Belgium-Based Medanex Clinic
March 30, 2022
Healthcare Services
NAMSA, a global MedTech contract research organization (CRO), announced it is nearing the acquisition of Medanex Clinic, a Belgium-based European preclinical research organization. The deal is intended to expand NAMSA’s early-stage preclinical and specifically cardiovascular preclinical capabilities in Europe.
-
Novaremed AG Acquires Metys Pharmaceuticals AG
September 7, 2021
Pharmaceuticals
Novaremed AG acquired Metys Pharmaceuticals AG in an all-share transaction, integrating Metys' clinical and preclinical non-opioid pain programs (including MP-101 and MP-103) into Novaremed's pipeline. The deal broadens Novaremed's focus from painful diabetic peripheral neuropathy (PDPN) to include chemotherapy-induced peripheral neuropathy (CIPN) and strengthens leadership with the election of Andrew J. Oakley to Novaremed's board.
-
HOPE Therapeutics (NRx Pharmaceuticals) to Acquire Dura Medical
March 31, 2025
Healthcare Services
HOPE Therapeutics, wholly owned by NRx Pharmaceuticals, signed a definitive agreement to acquire Dura Medical (Dura) following a prior letter of intent. The acquisition is intended to expand HOPE’s network of interventional psychiatry clinics on Florida’s west coast and support a planned international rollout, with Dura providing revenue-generating and EBITDA-positive operations.
-
SSI Strategy Acquires NDA Group AB
August 15, 2023
Healthcare Services
SSI Strategy has entered into a definitive agreement to acquire NDA Group AB, a regulatory affairs and drug development consultancy, to create an integrated life sciences consultancy offering end-to-end drug development and regulatory services. The combination, supported by SSI's private equity partner Amulet Capital Partners, expands SSI's regulatory capabilities and geographic footprint across the U.S. and Europe.
-
Novartis Acquires DTx Pharma
July 17, 2023
Biotechnology
Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.
-
ArchiMed Acquires Majority Stake in NAMSA
September 1, 2020
Healthcare Services
ArchiMed, a healthcare-focused private equity firm, acquired a majority interest in NAMSA from the founding Gorski Family in an undisclosed equity recapitalization. NAMSA's president and senior management retained a significant double-digit stake; ArchiMed said the investment will support NAMSA's international growth and buy‑and‑build strategy to broaden services and accelerate expansion.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.